• Go to navigation
  • Go to content
AstraZeneca

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca United States

Main navigation

  • Home
  • Our medicines
  • Diseases and conditions
  • Community support
  • Help affording your medicines
  • Research & development
  • Healthcare professionals
  • Careers
  • About AstraZeneca US
    • Investors
    • Our company
    • AZ on the issues
    • Responsible business
    • Newsroom
      • Media resources
      • All news
      • Corporate news
      • Financial news
      • Product news
      • Research news
    • US web sites
    • Contact us

You are here

  • Home
  • About AstraZeneca US
  • Newsroom
  • Product news

The following shows headlines of all product-related news articles published within 12-months, starting from most recent.

  • Pages
  • 1
  • 2
  • 3
  • Next

Date

    • Nov 17, 2009
    • CRESTOR® reduced risk of cardiovascular events in women by nearly half in new analysis of JUPITER study  
    • Nov 9, 2009
    • New post-hoc, pooled analysis shows SYMBICORT® improved airflow obstruction in patients with COPD  
    • Oct 16, 2009
    • U.S. Food and Drug Administration approves CRESTOR® for use in pediatric patients with heterozygous familial hypercholesterolemia  
    • Sep 25, 2009
    • US Court of Appeals affirms Summary Judgment decision in SEROQUEL® patent litigation  
    • Sep 1, 2009
    • AstraZeneca encourages all Americans to get their cholesterol checked during National Cholesterol Education Month in September  
    • Aug 31, 2009
    • CRESTOR® reduced risk of cardiovascular events in elderly patients in new analysis of JUPITER  
    • Aug 14, 2009
    • ONGLYZA™ (saxagliptin), a new treatment for type 2 diabetes mellitus in adults, now available in U.S. pharmacies  
    • Jul 31, 2009
    • U.S. Food and Drug Administration approves ONGLYZA™ (saxagliptin) for the treatment of type 2 diabetes mellitus in adults  
    • Jun 10, 2009
    • Favorable vote from FDA Advisory Committee on SEROQUEL pediatric Supplemental New Drug Applications  
    • Jun 4, 2009
    • AstraZeneca and Abbott extend relationship to include co-promotion of TRILIPIX® (fenofibric acid)  
  • Pages
  • 1
  • 2
  • 3
  • Next

Page tools

  • Print
  • Bookmark this page
  • Subscribe to RSS news feed

Follow us on Twitter

Follow AstraZenecaUS on Twitter

Legal notices

  • Legal Information
  • Privacy Statement
  • © AstraZeneca 2009